PureTech Health plc Stock
Stocks
PRTC
GB00BY2Z0H74
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 119.60 GBX | -1.16% |
|
-3.08% | -4.32% |
| 07-13 | PureTech Health announces first patient dosing in Celea phase 3 trial | AN |
| 07-13 | PureTech Health: Celea Therapeutics Kicks Off Late-stage Trial for Idiopathic Pulmonary Fibrosis Drug | MT |
| Market Cap | 387M 336M 312M 288M 542M 36.92B 552M 3.69B 1.45B 18.34B 1.45B 1.42B 61.67B | P/E 2026 * |
-3.52x | P/E 2027 * | -4.2x |
|---|---|---|---|---|---|
| Enterprise Value | 118M 102M 95.04M 87.65M 165M 11.25B 168M 1.13B 441M 5.59B 442M 433M 18.79B | EV / Sales 2026 * |
16.6x | EV / Sales 2027 * | 10.6x |
| Free-Float |
84.53% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: PureTech Health plc
| 1 day | -1.24% | ||
| 1 week | -3.08% | ||
| Current month | -12.95% | ||
| 1 month | -12.95% | ||
| 3 months | -6.27% | ||
| 6 months | -9.67% | ||
| Current year | -4.32% |
| 1 week | 117.4 |  | 124.2 |
| 1 month | 115 | | 139 |
| Current year | 107.4 | | 143.6 |
| 1 year | 104.71 | | 146.4 |
| 3 years | 100.4 | | 238.5 |
| 5 years | 100.4 | | 410.66 |
| 10 years | 100.4 | | 447.66 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Lyne
CEO | Chief Executive Officer | 43 | 15/07/2025 |
Eric Elenko
PSD | President | 53 | 09/04/2024 |
Charles Sherwood
COO | Chief Operating Officer | - | 01/08/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Langer
BRD | Director/Board Member | 76 | 08/05/2015 |
John LaMattina
BRD | Director/Board Member | 76 | 01/01/2009 |
| Director/Board Member | 73 | 01/10/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 24/09/25 | Buy | Chief Executive Officer | 81,051 | 0.0337% | ||
| 24/09/25 | Buy | Director | 29,239 | 0.0122% | ||
| 24/09/25 | Buy | Chairman | 65,250 | 0.0272% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.16% | -3.08% | -17.40% | -46.49% | 391M | |
| -0.80% | +5.16% | -0.70% | +12.87% | 48.95B | |
| -3.88% | +14.55% | +23.99% | +6.14% | 40.75B | |
| +5.92% | +1.25% | +416.30% | +628.04% | 38.46B | |
| -1.34% | -1.43% | +7.38% | +50.35% | 36.38B | |
| +5.56% | +11.70% | +11.64% | +51.50% | 28.45B | |
| -1.76% | -1.84% | - | - | 16.62B | |
| -0.81% | -4.74% | +31.82% | +127.94% | 16.33B | |
| -7.60% | -3.46% | -9.41% | -34.60% | 13.65B | |
| -0.06% | +3.75% | +3.16% | +10.08% | 13.56B | |
| Average | -0.53% | +5.80% | +51.87% | +89.54% | 25.35B | |
| Weighted average by Cap. | +0.11% | +7.51% | +75.90% | +126.92% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.1M 6.17M 5.73M 5.28M 9.95M 678M 10.13M 67.8M 26.55M 337M 26.66M 26.08M 1.13B | 13.47M 11.7M 10.86M 10.02M 18.87M 1.29B 19.21M 129M 50.35M 639M 50.57M 49.46M 2.15B |
| Net income | -124M -108M -100M -92.32M -174M -11.85B -177M -1.19B -464M -5.88B -466M -456M -19.79B | -96.8M -84.08M -78.08M -72.01M -136M -9.24B -138M -924M -362M -4.59B -364M -356M -15.43B |
| Net Debt | -269M -234M -217M -200M -377M -25.67B -384M -2.57B -1.01B -12.75B -1.01B -988M -42.88B | -244M -212M -197M -182M -342M -23.33B -349M -2.33B -914M -11.59B -918M -898M -38.96B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/07/26 | GBX 119.60 | -1.16% | 615,375 |
| 29/07/26 | GBX 121.00 | +2.37% | 926,652 |
| 28/07/26 | GBX 118.20 | -3.11% | 419,236 |
| 27/07/26 | GBX 122.00 | -0.81% | 328,816 |
| 24/07/26 | GBX 123.00 | -0.32% | 301,399 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PRTC Stock
Select your edition
All financial news and data tailored to specific country editions
